Wednesday, September 24, 2025

Merck and Siemens Join Forces to Accelerate AI-Powered Drug Development

Merck, a leading science and technology company, and Siemens, a global technology leader, have extended their strategic partnership through a new Memorandum of Understanding (MoU) to drive digital transformation in the life sciences sector.

The focus lies on creating integrated software solutions and systems that combine automation, data, and artificial intelligence (AI) to optimize the entire process from drug discovery to biopharmaceutical manufacturing.

The MoU marks the first joint use of technology acquired by Siemens through the Dotmatics acquisition in July 2025. Initial pilot projects include the integration of Merck’s AI tools into “Luma,” Siemens’ Dotmatics Scientific Intelligence Platform, enabling scientists to access digital applications directly and make faster, data-driven decisions.

Jean-Charles Wirth, CEO Life Science at Merck, emphasized: “Through this collaboration, we open new possibilities for scientists to move faster from an idea in the lab to a therapy for patients.” Cedrik Neike, CEO Siemens Digital Industries, added: “Data, AI, and digitalization are key to breaking the rising cost paradigm in drug development.”

Looking ahead, both companies plan to co-develop additional digital tools, intuitive interfaces, and marketplaces to simplify access to complementary technologies and services. The partnership aims to set a new standard for digital innovation in life sciences and enable accelerated scientific breakthroughs.